Clinical Trial: Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma

U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07917832) titled 'Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma' on Nov. 03.

Brief Summary: To learn if the combination of golcadomide, obinutuzumab, glofitamab, and polatuzumab vedotin in LBCL participants can help to control the disease.

Study Start Date: April 29, 2027

Study Type: INTERVENTIONAL

Condition: Multi Center Phase 2 Golcadomide Glofitamab Polauzumab Vedotin G2p B Cell Lymphoma

Intervention: DRUG: golcadomide

By mouth on Days 1-7 of each cycle

DRUG: Obinutuzumab

by vein over approximately 4-5 hours

DRUG: Polatuzumab

by vein ...